Visus presbyopia drop gets FDA IND OK

April 9, 2021
Rhett Schiffman, MD, MHSA

,
Gretchyn M. Bailey, NCLC, FAAO, Editor in Chief, Content Channel Director

,
Brooke Beery, Associate Editor
Brooke Beery, Associate Editor

Brooke Beery is Associate Editor of Optometry Times®.

A presbyopia-correcting eyedrop recently received FDA acceptance of its investigational new drug (IND) application

Rhett Schiffman, MD, MHSA, chief medical officer and head of research and development at Visus Therapeutics, talks with Gretchyn Bailey, NCLC, FAAO, editor in chief of Optometry Times® about Brimichol, the company’s presbyopia-correcting eyedrop that recently received FDA acceptance of its investigational new drug (IND) application.